Praxis Precision Medicines Inc (NASDAQ:PRAX) has a beta value of 2.67 and has seen 0.49 million shares traded in the recent trading session. The company, currently valued at $1.43B, closed the recent trade at $76.79 per share which meant it gained $2.11 on the day or 2.82% during that session. The PRAX stock price is -13.2% off its 52-week high price of $86.93 and 80.77% above the 52-week low of $14.77. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.34 million shares traded. The 3-month trading volume is 297.24K shares.
The consensus among analysts is that Praxis Precision Medicines Inc (PRAX) is Buy stock at the moment, with a recommendation rating of 1.30. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 1 out of 5 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -2.82.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Praxis Precision Medicines Inc (NASDAQ:PRAX) trade information
Sporting 2.82% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the PRAX stock price touched $76.79 or saw a rise of 1.82%. Year-to-date, Praxis Precision Medicines Inc shares have moved 244.64%, while the 5-day performance has seen it change 5.55%. Over the past 30 days, the shares of Praxis Precision Medicines Inc (NASDAQ:PRAX) have changed 7.05%. Short interest in the company has seen 1.72 million shares shorted with days to cover at 6.6.
Wall Street analysts have a consensus price target for the stock at $146.5, which means that the shares’ value could jump 47.58% from the levels at last check today. The projected low price target is $120.0 while the price target rests at a high of $170.0. In that case, then, we find that the latest price level in today’s session is -121.38% off the targeted high while a plunge would see the stock gain -56.27% from the levels at last check today.
Praxis Precision Medicines Inc (PRAX) estimates and forecasts
Figures show that Praxis Precision Medicines Inc shares have outperformed across the wider relevant industry. The company’s shares have gained 66.49% over the past 6 months, with this year growth rate of 45.10%, compared to 17.90% for the industry. Revenue growth from the last financial year stood is estimated to be -40.38%.
10 analysts offering their estimates for the company have set an average revenue estimate of 365k for the current quarter. 7 have an estimated revenue figure of 221.71k for the next ending quarter. Year-ago sales stood 515k and 431k respectively for this quarter and the next, and analysts expect sales will shrink by -29.13% for the current quarter and -40.38% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -10.28% over the past 5 years. Earnings growth for 2024 is a modest 45.43% while over the next 5 years, the company’s earnings are expected to decrease by -14.60%.
PRAX Dividends
Praxis Precision Medicines Inc is expected to release its next earnings report in December this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Praxis Precision Medicines Inc (NASDAQ:PRAX)’s Major holders
Insiders own 0.24% of the company shares, while shares held by institutions stand at 104.05% with a share float percentage of 104.30%. Investors are also buoyed by the number of investors in a company, with Praxis Precision Medicines Inc having a total of 190.0 institutions that hold shares in the company.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of Jun 30, 2024, the former fund manager holds about 2.79% shares in the company for having 520.52 shares of worth $40.15 million while later fund manager owns 445.26 shares of worth $34.34 million as of Sep 30, 2024, which makes it owner of about 2.39% of company’s outstanding stock.
